Moreover, the combination of an HDAC inhibitor (entinostat) with HER2 + targeted therapeutic agents (lapatinib and trastuzumab) significantly enhanced the apoptosis of trastuzumab-resistant IBC tumour cells in a preclinical model [75]. The gene discussed is HDAC9; the disease is inflammatory breast carcinoma.